Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 in Perioperative Treatment of Locally Advanced MSI-H/dMMR Gastric and Colorectal Cancers
NCT04556253Phase 2Active, not recruiting
- Sponsor
- Peking University
- Start
- Feb 2024
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in Gastric carcinoma (GC) and colorectal cancer (CRC), sponsored by Peking University. Primary endpoint: Pathologic Complete Response Rate at 1 year. Started Feb 2024; status: active, not recruiting.
02
Drugs
cadonilimab
03
Conditions
Gastric carcinoma (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04556253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04556253.